Alkem Laboratories Ltd (ALKEM) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Alkem Laboratories Ltd. concluded FY2025 with robust performance in the India business, marked by healthy Q4 growth and improved profitability and margins for the full year.
- The domestic business exhibited strong momentum, driven by effective execution and targeted initiatives.
- International business, excluding the Americas, demonstrated positive traction, with key markets contributing significantly to growth.
- The company outperformed the Indian Pharmaceutical Market (IPM) in terms of volume growth by 90 basis points, registering 2.1% growth.
- Alkem holds the third-largest prescription share and ranks among the top players in various specialties, including being number 1 in ortho.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.